以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要 从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上 线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其 他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。 证券之星消息，12月11日南向资金增持49.95万股复星医药（02196.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持143.7万股。近20个交易日中，获南向资金增持的有13天，累计净增持180.6万 股。截至目前，南向资金持有复星医药（02196.HK）3.16亿股，占公司已发行普通股的57.28%。 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Fosun Pharma (02196.HK) by 1.714 million shares on September 18, 2025, while experiencing a net reduction of 1.861 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Fosun Pharma for 15 days, resulting in a total net reduction of 26.2152 million shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on September 18, 2025, was 321 million, reflecting a change of 1.714 million shares, or an increase of 0.54% [2] - On September 17, 2025, the total shares held decreased by 4.086 million shares, representing a decline of 1.27% [2] - Fosun Pharma operates in five segments, including pharmaceuticals, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2]